Physician profile
Caleb Vass
NPI 1588198949
$4,952.94
in general payments reported to CMS, 2019-2025
32 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $107 · 2021: $467 · 2022: $374 · 2023: $872 · 2024: $1,346 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $762.80 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $681.88 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $386.33 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $377.49 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.63 | 2022-2025 | Caplyta |
| Pfizer INC. | $298.40 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $258.00 | 2023-2025 | Rexulti |
| Amgen INC. | $250.32 | 2023-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $222.75 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $196.14 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $136.59 | 2024-2025 | Freestyle Libre 3, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.89 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $127.57 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $99.71 | 2024 | Hetlioz, Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.70 | 2022-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $85.85 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $61.89 | 2024-2025 | Voquezna |
| Allergan, INC. | $55.93 | 2020-2021 | |
| Astellas Pharma US INC | $46.68 | 2023-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $46.05 | 2023-2025 | Spravato, Xarelto |
| Insulet Corporation | $41.59 | 2024-2025 | Omnipod |
| Axsome Therapeutics, INC. | $39.11 | 2024-2025 | Auvelity, Sunosi |
| Esperion Therapeutics, INC. | $34.41 | 2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $33.31 | 2024 | Gvoke Hypopen |
| Alkermes, INC. | $28.71 | 2025 | Lybalvi, Aristada |
| Dexcom, INC. | $24.04 | 2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $19.92 | 2022 | |
| Lundbeck LLC | $19.58 | 2025 | Rexulti |
| Acella Pharmaceuticals, LLC | $16.58 | 2025 | NP Thyroid 60 |
| Paratek Pharmaceuticals, INC. | $13.75 | 2025 | Nuzyra, Xhance |
| Ardelyx, INC. | $13.64 | 2025 | Ibsrela |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Vass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.